FILING ANALYSIS · THURSDAY, NOVEMBER 12
ALUMIS INC. ALMS — 8-K: Results of Operations and Financial Condition
neutral
Alumis reported strong Phase 3 data for envudeucitinib in plaque psoriasis, with a 54% PASI 100 response rate, and remains on track for a 4Q 2026 NDA submission, but the Phase 2b LUMUS trial for envudeucitinib in systemic lupus erythematosus did not meet primary and secondary endpoints in the overall population, although it showed promise in a prespecified subgroup analysis
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →